Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
A Pilot, Double-Blind, Randomized, Two-Arm Crossover Study of Doxepin Versus Placebo for Esophagitis-Induced Pain in Patients Receiving Radiotherapy to the Thorax With or Without Chemotherapy
Sponsor: Mayo Clinic
Terminated
Poor accrual
Other terminated trials from Mayo Clinic
Other Esophageal Carcinoma trials with similar outcome
This PHASE2 trial investigates Esophageal Carcinoma and Hypopharyngeal Carcinoma and is currently terminated or withdrawn. Mayo Clinic leads this study, which shows 9 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE2
Status: Completed → Terminated · Phase: NA → PHASE2
-
Dec 2018 — Nov 2019 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting NA
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .